ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1745

Chronic Inflammation and Collagen IV Fragment Canstatin Influence Rheumatoid Arthritis Synovial Fibroblast and Endothelial Cell Interactions in Vitro and in Vivo

Corinna Heck1, Sophie Haun1, Daria Kürsammer1, Klaus Frommer1, Mona Arnold1, Markus Rickert2, Katrin Susanne Lips3, Stefan Rehart4, Ulf Müller-Ladner1 and Elena Neumann1, 1Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, 2Dept. of Orthopaedics and Orthopaedic Surgery, University Hospital Giessen and Marburg, Giessen, Germany, 3Justus Liebig University Gießen, Department of Experimental Trauma Surgery, Giessen, Germany, 4Dept. of Orthopaedics and Trauma Surgery, Agaplesion Markus Hospital Frankfurt, Frankfurt, Germany

Meeting: ACR Convergence 2023

Keywords: Angiogenesis, Collagen, Fibroblasts, Synovial, Inflammation, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: (1734–1775) RA – Etiology and Pathogenesis Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: In the inflamed synovium of RA patients, increased and altered angiogenesis is a pathological feature. Key players are chronically activated RA synovial fibroblasts (RASF), which promote synovial angiogenesis and matrix degradation. Canstatin is a matrix-derived anti-angiogenic collagen IV fragment that blocks the angiopoietin (ANGPT)/Tie2 pathway in endothelial cells (EC).

Objective: To analyse the effects of repetitively stimulated RASF and canstatin on vessel formation in the tube formation assay, the SCID-mouse model of RA and synovial tissue of RA patients with respect to ANGPT2 expression and RASF-EC interactions.

Methods: RASF were repetitively stimulated thrice every 24h with 0.05ng/ml IL-1ß. 2D tube formation assay was performed using HUVEC (+/- prestimulation with 0.2µg/ml canstatin for 20h) and 15%RASF seeded on Matrigel®. RASF/HUVEC were treated with 0.5µg/ml canstatin. Tube thickness and the area covered by the formed cellular network were measured. Supernatants were measured by ELISA. Cartilage was subcutaneously co-implanted with RASF alone or with 0.5µg/ml canstatin into SCID mice. Contralaterally, cartilage without RASF but with canstatin was implanted. Vessel formation and RASF-invasion were evaluated after 3-45 days.

Results: RASF or HUVEC stimulated once showed a significant IL-6 increase compared to unstimulated controls. Subsequent repetitive stimulation resulted in a significant IL-6 decrease compared to 1st stimulation in RASF (1st vs. 3rd: p< 0.0001) or HUVEC (1st vs. 3rd: p=0.041). The same effect was observed for IL-11 and CXCL2 in RASF (1st: vs. 3rd: p< 0.0001). In contrast, repetitive stimulation of HUVEC+15%RASF resulted in a significant IL-6 increase for each subsequent stimulation (1st vs. 3rd: p=0.02). Regarding tube formation, RASF significantly reduced tube thickness (p=0.01) and cell network area (p < 0.0001). RASF stimulated only once further reduced the network area (p=0.04), while repetitive stimulation significantly attenuated the proinflammatory effect (p=0.03). Stimulation of pre-treated HUVEC and unstimulated RASF with canstatin led to disturbed tube formation with reduced tube thickness (p=0.01). Co-culture of RASF with pre-treated HUVEC with canstatin further increased the RASF-mediated effect by reducing tube thickness (p < 0.001). In SCID mice, RASF-mediated helix-like vessel formation started at day 3. Number of helix-like vessels was significantly increased ipsilaterally compared to contralateral implants on day 3 and 30 (p=0.04). In contrast, number of helix-like vessels was significantly reduced ipsilaterally in implants containing canstatin on day 3 and 30 (p=0.03 both). In human RA synovium, the pathological vessel regulator ANGPT2 was significantly upregulated in vessels compared to OA tissue.

Conclusion: RASF-mediated effects on EC were detectable in the tube formation assay, since RASF and canstatin both specifically reduced tube thickness. RASF specifically altered neovascularization in SCID mice by promoting the formation of helix-like vessels. Human synovial tissue of RA patients showed significantly upregulated ANGPT2 expression compared to OA patients showing the effects on vessel formation in RA.


Disclosures: C. Heck: None; S. Haun: None; D. Kürsammer: None; K. Frommer: None; M. Arnold: None; M. Rickert: None; K. Lips: None; S. Rehart: None; U. Müller-Ladner: None; E. Neumann: None.

To cite this abstract in AMA style:

Heck C, Haun S, Kürsammer D, Frommer K, Arnold M, Rickert M, Lips K, Rehart S, Müller-Ladner U, Neumann E. Chronic Inflammation and Collagen IV Fragment Canstatin Influence Rheumatoid Arthritis Synovial Fibroblast and Endothelial Cell Interactions in Vitro and in Vivo [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/chronic-inflammation-and-collagen-iv-fragment-canstatin-influence-rheumatoid-arthritis-synovial-fibroblast-and-endothelial-cell-interactions-in-vitro-and-in-vivo/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/chronic-inflammation-and-collagen-iv-fragment-canstatin-influence-rheumatoid-arthritis-synovial-fibroblast-and-endothelial-cell-interactions-in-vitro-and-in-vivo/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology